Navigation Links
Pulmonary Fibrosis Contributes to Beloved Civil Rights Writer and Folk Singer Odetta's Death
Date:12/4/2008

SAN JOSE, Calif., Dec. 4 /PRNewswire-USNewswire/ -- Music and civil rights icon Odetta succumbed December 2 as a result of multiple illnesses. One of them was pulmonary fibrosis (PF), an illness that relentlessly fills the lungs with scar tissue and suffocates its victims, and is one of the deadliest yet least well known diseases in the country. Despite being diagnosed with PF two years ago, a diagnosis that was essentially a death sentence, Odetta went on to perform extraordinary concerts all over the world. Her doctors were amazed at her determination to sing while battling the disease. Despite her markedly reduced lung capacity, she managed to complete entire concerts and only access her supplemental oxygen as she left the stage.

Pulmonary Fibrosis (PF) is a tissue debilitating lung disease that causes progressive scarring of the lungs, ultimately robbing a person of the ability to breathe. As many people die each year to PF as to breast cancer, yet most have never heard of it until they receive the devastating diagnosis. More than 128,000 suffer from the disease and incidence and prevalence has increased more than 150 percent in the last several years.

"We are deeply saddened at the loss of such a beloved singer and civil rights legend," said Mishka Michon, chief executive officer for the Coalition for Pulmonary Fibrosis (CPF). "We lose 40,000 people a year to this disease (as many as are lost to breast cancer), and each loss is painful. Odetta's death highlights for the nation, and for her fans, what those of us fighting pulmonary fibrosis already know - that there is a killer disease randomly striking thousands and we have no treatments. Marlon Brando, Gordon Jump and Robert Goulet's lives were among those cut down by pulmonary fibrosis - we don't want to see these losses continue at their current pace. We can only hope that, with increased awareness and funding for research, the future will change for others."

Odetta's manager, Doug Yeager, told the CPF she was diagnosed with PF two years ago but refused to let the grim prognosis get her down. Most patients live less than three years and few are able to continue a normal life because of the extremely life limiting breathlessness and related exhaustion.

Odetta used supplemental oxygen for the two years she suffered, but somehow had the strength to perform more than 60 concerts after her diagnosis around the world - all of her performances except for one were completed without her having to use an oxygen tank, Yeager said.

"She wouldn't use her oxygen during her concerts. Somehow, she'd go out and sing for 90 minutes without it," Yeager said. The only concert she performed with supplemental oxygen was one in Denver, Colorado, a city that sits at 5,280 feet of elevation, he said.

There is no FDA approved treatment for PF, no known cause and no cure. Odetta is one of 40,000 people who will die this year from the disease. The CPF has counseled thousands of patients and family members who've faced pulmonary fibrosis. To learn more, please visit: www.coalitionforpf.org.

Odetta's last concert performance was October 26th of this year, according to Yeager. She also performed a concert October 6th, in front of 100,000 people at San Francisco's Golden Gate Park.

About Pulmonary Fibrosis (PF)

PF is a lung disorder characterized by a progressive scarring - known as fibrosis - and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 128,000 Americans suffer from IPF, and there is currently no known cause or cure. An estimated 48,000 new cases are diagnosed each year. IPF is difficult to diagnose and an estimated two-thirds of patients die within five years of diagnosis. Sometimes pulmonary fibrosis can be linked to a particular cause, such as certain environmental exposures, chemotherapy or radiation therapy, residual infection, or autoimmune diseases such as scleroderma or rheumatoid arthritis. However, in many instances, no known cause can be established. When this is the case, it is called idiopathic pulmonary fibrosis (IPF).

About the CPF

The CPF is a 501(c)(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for pulmonary fibrosis (PF), while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF funds promising research into new approaches to treat and cure pulmonary fibrosis; provides patients and families with comprehensive education materials, resources, and hope; serves as a voice for national advocacy of PF issues; and works to improve awareness of PF in the medical community as well as the general public. The CPF's nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. With more than 16,000 members nationwide, the CPF is the largest nonprofit organization in the U.S. dedicated to advocating for those with pulmonary fibrosis. For more information please visit www.coalitionforpf.org or call (888) 222-8541.


'/>"/>
SOURCE Coalition for Pulmonary Fibrosis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CPF Updates Patient Education Materials to Meet Growing Demand for Pulmonary Fibrosis Information
2. Pulmonary Hypertension Treated with Stem Cells : International Medical Team Announces Patient Results in Adult Stem Cell Clinical Study for Pulmonary Hypertension
3. Co-Sponsorship of Pulmonary Fibrosis Research Enhancement Act Increases to 27 Members
4. Viagra Bulk Effectively Cures Children with PAH (Pulmonary Arterial Hypertension)
5. Women at Higher Risk for Pulmonary Hypertension
6. Cialis May Help Ease Pulmonary Hypertension
7. Tomophase to Exhibit First In-vivo Cross-sectional Images of Pulmonary Stenting Using Proprietary OCT System
8. Eisai Inc. Supports Acting Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
9. The U.S. Surgeon General Issues National Call-to-Action on Deep-Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
10. LSUHSC study finds high-dose HBO2 therapy extends survival window after cardiopulmonary arrest
11. American Lung Association Commends U.S. House of Representatives for Passage of Pulmonary and Cardiac Rehabilitation Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... ... care communications company offering education, research and medical media, has launched ... working in infectious diseases. , As the all-inclusive resource for infectious disease ...
(Date:2/10/2016)... ... February 10, 2016 , ... MetLoop CEO Jay Southerland ... version at the International Roofing Expo in Orlando, Florida on February 17-19. , ... advanced weather technology in the hands of consumers, roofing contractors, manufacturers and distributors,” ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... and Video Remote Interpreting (VRI) within Healthcare, recently partnered with Heart City ... interpreting (VRI). , For nearly 23 years, Heart City Health Center has provided ...
(Date:2/10/2016)... Huntington, NY (PRWEB) , ... February 10, 2016 ... ... web-based compliance tracking solution, The Guard, to associations of medical professionals throughout the ... HIPAA compliance, including security risk assessments, policies and procedures, employee training, regulatory updates, ...
(Date:2/10/2016)... ... ... Emergency rooms provide emergency care to stabilize critical health issues, but emergency dental ... at risk of losing a tooth or their smiles. Dr. Marine Martirosyan, dentist ... include:, , Avulsed or knocked-out teeth , Dislodged ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... -- Resolve Therapeutics, LLC, a clinical stage biopharmaceutical company ... of lupus and Sjogrens syndrome, today announced the ... in patients with systemic lupus erythematosus (SLE) with ... --> Data from a multicenter ... RSLV-132 in 32 subjects with SLE demonstrate the ...
(Date:2/10/2016)... NEW YORK , Feb. 10, 2016 ... clinical-stage biopharmaceutical company, announced today that it has filed ... Myeloid Leukemia and other cancers. --> ... of treating cancer by administration of Ceplene (histamine dihydrochloride) ... also provides methods of predicting the efficacy of Ceplene ...
(Date:2/10/2016)... A Worldwide Clinical Trials expert will ... Victoria Park Plaza in London , 24-25 ... and future advances for late phase research on Wednesday, 24 ... , associate director of project management at Worldwide, will focus ... regulations and standards in late phase research. ...
Breaking Medicine Technology: